Wellbutrin is classified as a norepinephrine-dopamine reuptake inhibitor, or NDRI. It is the only antidepressant in this class available in the United States, which makes it distinct from the more commonly prescribed SSRIs, SNRIs, and tricyclic antidepressants. Its chemical structure belongs to a group called aminoketones, and the FDA describes it as “chemically unrelated” to every other known class of antidepressant.
How an NDRI Works
Your brain uses chemical messengers called neurotransmitters to regulate mood, motivation, focus, and energy. After a neurotransmitter delivers its signal, it normally gets pulled back into the nerve cell that released it, a process called reuptake. Wellbutrin blocks the reuptake of two specific neurotransmitters: norepinephrine (which influences alertness and energy) and dopamine (which plays a role in motivation, pleasure, and reward).
By keeping more dopamine and norepinephrine available in the spaces between nerve cells, Wellbutrin can improve depressive symptoms through a completely different pathway than most antidepressants. Clinical and preclinical studies confirm that bupropion, the generic name for Wellbutrin, acts as a dual reuptake inhibitor of both neurotransmitters at standard prescribed doses.
How It Differs From SSRIs
SSRIs like sertraline (Zoloft) and escitalopram (Lexapro) work by increasing serotonin levels. Wellbutrin does not significantly affect serotonin at all. This is the single biggest distinction and the reason Wellbutrin’s side effect profile looks so different from most antidepressants.
Because SSRIs raise serotonin, they commonly cause weight gain, sexual dysfunction, and drowsiness. Wellbutrin tends to avoid all three. In fact, it is sometimes added to an SSRI specifically to counteract sexual side effects or the emotional blunting some people experience on serotonin-based medications. It also has a mildly stimulating quality, which can help with fatigue and low motivation but may worsen anxiety in some people.
FDA-Approved Uses
Wellbutrin is approved to treat major depressive disorder. That is its only approved indication under the Wellbutrin brand name. However, the same active ingredient, bupropion, appears in several other branded products approved for different conditions:
- Zyban: approved for smoking cessation
- Contrave: a combination of bupropion and naltrexone, approved for chronic weight management in adults with a BMI of 30 or higher (or 27 or higher with a weight-related condition like high blood pressure or type 2 diabetes)
Because these products all contain bupropion, you should never take more than one of them at the same time. Doing so increases seizure risk.
Common Off-Label Uses
Surveys show that over 20% of bupropion prescriptions are written for off-label purposes. The most common include ADHD in adults, where a controlled trial found it significantly reduced inattention and executive function symptoms. It is also used for bipolar depression (as an add-on to a mood stabilizer), SSRI-induced emotional blunting, and mood symptoms related to perimenopause. A 2023 trial found it improved fatigue and functional capacity in women with fibromyalgia.
Available Formulations
Wellbutrin comes in three release formats, and the distinction matters because it affects how many times a day you take it and how steady the drug levels stay in your bloodstream:
- Wellbutrin IR (immediate release): taken two to three times daily
- Wellbutrin SR (sustained release): taken twice daily, with at least eight hours between doses
- Wellbutrin XL (extended release): taken once daily
Forfivo XL and Aplenzin are additional brand names for extended-release bupropion. All contain the same active drug. The extended-release versions were developed primarily for convenience and to reduce the peak-and-trough pattern that can come with multiple daily doses.
Seizure Risk and Key Safety Concerns
The most important safety consideration with Wellbutrin is seizure risk, which increases at higher doses. This is why there is a firm daily dose ceiling and why combining bupropion products is contraindicated. Certain groups face higher risk:
- People with a current or past seizure disorder
- People with a current or prior diagnosis of anorexia or bulimia, where a higher seizure rate has been documented
- People going through abrupt withdrawal from alcohol or sedatives, including benzodiazepines
- People with a history of head trauma, a central nervous system tumor, or severe liver disease
Excessive alcohol use, stimulant use, and diabetes treated with insulin or oral medications can also raise seizure risk. Wellbutrin cannot be taken within 14 days of using an MAO inhibitor, an older class of antidepressant, due to the risk of a dangerous interaction.
For most people at standard doses, seizures are rare. But the dose-dependent nature of this risk is why prescribers are careful about titration and why crushing, snorting, or injecting the tablets, which bypasses the controlled-release mechanism, is particularly dangerous.